Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

Kim A. Johnson and Chandra Prakash
Drug Metabolism and Disposition August 2005, 33 (8) 1191-1201; DOI: https://doi.org/10.1124/dmd.105.004713
Kim A. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Prakash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 33 no. 8 1191-1201
DOI 
https://doi.org/10.1124/dmd.105.004713
PubMed 
15886349

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received March 14, 2005
  • Accepted May 9, 2005
  • Published online July 13, 2005.

Article Versions

  • Earlier version (May 10, 2005 - 11:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Kim A. Johnson and
  2. Chandra Prakash
  1. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut
  1. Address correspondence to:
    Dr. Chandra Prakash, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, CT 06340. E-mail: Chandra.Prakash{at}Pfizer.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to September 2023

AbstractFullPdf
Aug 20173177
Sep 201703117
Oct 20173166
Nov 20170385
Dec 20172204
Jan 20182213
Feb 20181236
Mar 20180205
Apr 20182312
May 20180214
Jun 20181275
Jul 20180122
Aug 20180173
Sep 20180132
Oct 20180111
Nov 20180393
Dec 2018933
Jan 20191602
Feb 2019901
Mar 20191202
Apr 20191703
May 20191513
Jun 20194111
Jul 20191514
Aug 20191301
Oct 20191210
Nov 20192100
Dec 20192613
Jan 20202512
Feb 20201211
Mar 2020901
May 2020810
Jun 2020400
Jul 20201100
Aug 20201403
Sep 2020631
Oct 20201505
Nov 20201011
Dec 20201110
Jan 20211522
Feb 20211246
Mar 20211410
Apr 20211222
May 2021820
Jun 20211220
Jul 20211120
Aug 2021812
Sep 2021511
Oct 20211510
Nov 20211514
Dec 20212311
Jan 2022412
Feb 2022920
Mar 2022520
Apr 20221311
May 20221202
Jun 20221811
Jul 20221418
Aug 2022611
Sep 20221410
Oct 2022711
Nov 20222216
Dec 20221713
Jan 20231137
Feb 20231312
Mar 20231312
Apr 20231021
May 20232124
Jun 2023723
Jul 20232935
Aug 2023214
Sep 20231114

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 33 (8)
Drug Metabolism and Disposition
Vol. 33, Issue 8
1 Aug 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

Kim A. Johnson and Chandra Prakash
Drug Metabolism and Disposition August 1, 2005, 33 (8) 1191-1201; DOI: https://doi.org/10.1124/dmd.105.004713

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS

Kim A. Johnson and Chandra Prakash
Drug Metabolism and Disposition August 1, 2005, 33 (8) 1191-1201; DOI: https://doi.org/10.1124/dmd.105.004713
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ontogeny of CPPGL
  • Expression of AKR and SDR Isoforms in the Human Intestine
  • Is Protein-Mediated Uptake Effect a Real Phenomenon?
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics